also lie within an intron of a parental protein-coding gene (intronic microRNAs). Similar to protein-coding genes, intergenic microRNAs have promoters that interact with RNA polymerase II and transcription factors, [3] [4] [5] permitting tissue-specific expression and signaldependent regulation. Intronic microRNAs are cleaved from the primary mRNA transcript, suggesting mRNA promoter-dependent transcription of these microRNAs. The primicroRNA molecule forms a hairpin structure recognized by the microprocessor complex containing the nuclear RNase III endonuclease, Drosha, and is rapidly processed to a 60-to 90-nucleotide stem loop RNA (~25-30 base pair stem). The resulting precursor microRNA (pre-microRNA) is actively transported from the nucleus through the nuclear export receptor, exportin 5. In the cytoplasm, the pre-microRNA is further processed by the RNAse III endonuclease, Dicer, which cleaves the precursor approximately 20 base pairs from the Drosha cut sites, thereby resulting in the formation of a short, double-stranded RNA molecule. The double-stranded microRNA associates with the RNA-induced silencing complex (RISC), where the RNA duplex is separated to yield a single-stranded mature microRNA, with strand selection based upon base-pair stability at the termini of the duplex. 6, 7 The "guide" strand typically loads into the RISC while the "passenger" strand (denoted by an asterisks; e.g., miR-199a*) is degraded. Recently, Kim et al 8 have demonstrated that the microRNA* can load into the RISC and suppress translation of target mRNA, suggesting that specific spatial and temporal cellular environments may influence strand selection and, ultimately, protein expression.
In addition to acute and epigenetic transcriptional regulation, the potential exists for microRNA expression regulation at any of the posttranscriptional processing steps. For instance, posttranscriptional regulation has been demonstrated at the level of Drosha 9,10 and/ or Dicer, 11 which enables the expression of either the primary or precursor microRNA, whereas expression of the mature, functional microRNA is inhibited. 9 This regulated processing has been observed in embryonic tissues and human primary tumors. 9 For example, Lin28, a developmentally regulated RNA binding protein that in conjunction with Nanog, Oct-4, and Sox2 can reprogram fibroblasts to pluripotency, 12 selectively blocks the processing of primary let-7 microRNAs in embryonic cells. 10 Interestingly, a Lin28 homolog, Lin28B, which also inhibits let-7 processing, is over-expressed in human hepatocellular carcinoma (HCC) as well as several cancer cell lines. Processing of the primary transcript can also include adenosine to inosine (A to I) editing by adenosine deaminases that act on RNA. 13 This RNA editing might result in decreased cleavage by Dicer 14 or, because inosine preferentially base pairs with guanosine, the modified nucleotide can alter target selection. 15 Therefore, as with mRNAs, the functional expression of microRNAs is a complex, highly regulated process including both transcriptional and posttranscriptional processes.
Function
Frequently, there is dissociation between mRNA expression and cellular protein levels; microRNA-induced suppression of translation is a possible mechanism for this. MicroRNAs function to "fine tune" cellular expression of proteins. Unlike short interfering RNAs (siRNAs), which are designed to target mRNA with 100% complementarity and promote mRNA degradation, microRNA binding to mRNAs requires fewer complementary bases. Complementary base pairing between the microRNA seed region (nucleotides 2-8) and the 3 untranslated region (UTR) of target mRNA is required for posttranscriptional gene silencing. However, recent reports have demonstrated the existence of microRNA targets within the coding sequence of several mRNAs. 16, 17 The degree of complementary base pairing over the entire length of the microRNA determines the mechanism of microRNAinduced mRNA translation suppression. Perfect or near-perfect complementarity between the microRNA and the mRNA results in mRNA degradation, similar to siRNA translational inhibition. 18 More frequently, translational suppression occurs when the microRNA seed region binds target mRNA with less complementarity throughout the entire sequence. The precise mechanism of translational suppression by this pathway is not defined clearly, but most likely involves recruitment of mRNAs to processing bodies, intracellular organelles in which mRNAs could be sequestered or degraded. 19 A recent report has described the microRNA-dependent sequestration of cationic amino acid transporter mRNA in hepatocyte processing bodies with subsequent release and rapid protein production during cellular stress. 20 Therefore, microRNA-induced sequestration of mRNAs inhibits translation; conversely, protein levels can be rapidly increased under specific cellular conditions through release of the mRNA from the processing body.
Recently, reports have also defined a role for microRNAs in hepatitis C virus (HCV) replication. 21 Specifically, miR-122 complementary sites were identified in both the 5 and 3 UTR of HCV RNA and were conserved among genotypes. The authors concluded that miR-122 does not affect viral RNA translation or stability but is likely recruited to the 5 UTR for viral RNA replication. This study not only defines a novel role of animal microRNAs in viral replication, but also is the first to suggest that animal microRNAs contribute to gene transcription through recruitment to the 5 UTR of transcripts.
Expression Profiling and Functional Analyses Expression Profiling
Modifications of common molecular protocols allow for the analysis of mature microRNA expression. Microarray, cloning, and real-time polymerase chain reaction (PCR)-based approaches are commonly performed for microRNA expression analyses. Several microarray platforms are available; each address issues of sensitivity and specificity in a different manner. In general, the isolated or enriched microRNAs are labeled and hybridized to arrays spotted with microRNA-specific probes and scanned to obtain the relative expression in a given sample. For cloning analyses, small RNAs are enriched and cloned, followed by sequencing to identify microRNAs and their relative abundance. 22, 23 Largescale, quantitative reverse transcriptase (RT) PCR is a technique frequently used to obtain the microRNA expression profile of a given sample. The small size of microRNAs precludes the use of standard RT PCR protocols; therefore, the reverse transcribed product must be extended before amplification. One way to achieve this is through the addition of a poly-A tail to mature microRNAs, which serves as a binding-site for oligo dT-primed reverse transcription. A 5 extension on the oligo dT primer, including a universal primer binding site, extends the length of the synthesized first strand. Specific amplification thus depends on primers complementary to individual microRNAs. Whereas expression analyses are required to identify microRNAs with altered expression patterns in diseased tissues, functional analyses of the ability of these microRNAs to regulate expression of target mRNAs are essential to understand their impact on pathogenic pathways and processes.
Functional Analyses
Functional data exist for a small percentage of microRNAs. These studies are frequently performed by transfecting precursor microRNAs or antisense-inhibitor microRNAs (antagomirs) into cells and using immunoblot analyses to identify resulting changes in protein levels. One obvious disadvantage of this technique, as with the transfection of siRNAs, is the potential for off-target effects. Report assays (typically with firefly luciferase or green fluorescent protein) are utilized to show functional interactions between microRNAs and the 3 UTR of a target mRNA. With this technique, the predicted target region of the mRNA is inserted into the 3 UTR of the reporter construct or the entire 3 UTR of the target mRNA is cloned at the 3 end of the reporter coding sequence. The plasmid construct can then be transfected and the expression of the reporter, if targeted by the microRNA of interest, correlates inversely with the amount of the microRNA of interest.
Short hairpin RNAs (shRNAs), structural and functional homologs of pre-microRNAs encoded in a plasmid or viral vector, can be used to increase the expression of a microRNA in a specific cell type; this technique can generate continuous cell lines or transgenic animals with stable and heritable gene silencing. A drawback of this technique is the potential to inhibit endogenous microRNA function through saturation of a limiting level of 1 factors involved in microRNA biogenesis. Studies have demonstrated that over-expressed shRNAs saturated the activity of exportin 5, a factor required for pre-microRNA export from the nucleus, and interfered with endogenous microRNA processing. 24, 25 In vivo studies have also demonstrated the toxicity of this approach as shRNA expression in the livers of adult mice resulted in significant fatality. 25 Furthermore, the expression of shRNAs can result in a nonspecific interferon response through RNA-activated protein kinase and interaction with Toll-like receptors (TLRs). Further optimization and regulation of shRNA expression, 25 as well as nucleotide modifications that limit immune stimulation, 26 could prove useful in moving this technology from bench to bedside.
Recently, locked nucleic acid (LNA) microRNA antagomirs were shown to be highly effective at modulating endogenous microRNA expression. LNA antagomirs, 1 type of modified antisense oligonucleotides (AMOs), are synthesized DNA molecules that contain modified ribose moieties in which the pentose sugar is constrained in the N-type conformation seen in A-form DNA. LNA-modified oligonucleotides have several advantages over standard antisense molecules. For example, the modified oligonucleotide increases thermal stability between the hybridized LNA molecule and target nucleotides, increasing binding affinity. [27] [28] [29] The LNA modification also enhances mismatch discrimination, compared with un-modified antisense molecules, resulting in increased target recognition. 30 Furthermore, LNA oligonucleotides exhibit high levels of stability (the LNA half-life in serum is reported to be ~15 hours, compared with ~12 hours for a 2 -Omethyl modified antisense molecule) 29 and solubility in aqueous solutions. 30 LNA-based microRNA probes are used commonly for in situ hybridization studies and array-based detection.
Several groups have developed microRNA knockout mice [31] [32] [33] or transgenic animals that over-express microRNAs [34] [35] [36] to study the roles of microRNAs in vivo. Zhao et al 31 developed miR-1-2 knockout mice to study heart development and observed partial embryonic lethality owing to abnormal heart morphogenesis. Those mice that survived to adulthood demonstrated heart defects, including increased cardiomyocyte proliferation and electrophysiologic defects. Additionally, Johnnidis et al 37 demonstrated that loss of function of a single miR-223 allele leads to an inflammatory lung pathology. The development of microRNA knockout mice is clearly a useful tool to improve our understanding of the relevance of microRNAs to GI function and disease.
MicroRNA Expression Profiles Are Altered in Malignant Diseases of the GI Tract
As with other complex gene regulatory networks, aberrant expression or processing of microRNAs could have profound effects on cellular function and contribute to disease states. Profiling studies have revealed that microRNA levels are dysregulated in hepatic, [38] [39] [40] [41] bile duct, 42 colon, 43, 44 and pancreatic [45] [46] [47] cancer cells. For example, members of the miR-17-92 cluster, as well as miR-21, miR-224, and miR-221/222, were typically expressed at higher levels in HCC tissues compared with normal tissues. Of interest, levels of let-7 family members, miR-29 family members and miR-103/107 were all dysregulated, but were either over-expressed or under-expressed in different tumor samples. These variations might have resulted from different methodologies or predisposing risk factors and etiologies of the HCCs studied. In colon cancer tissues, several microRNAs were expressed at altered levels in independent expression analysis studies. For example, miR-143 and miR-145 were consistently down-regulated, 43, 48, 49 whereas miR-21 was consistently upregulated 43, 48, 49 in colorectal tumor samples versus normal tissues. Additionally, microRNA expression analysis of pancreatic tumors or cell lines derived from pancreatic tumors demonstrated altered expression compared with normal pancreatic tissue. Pancreatic tumors, regardless of histologic type, could be distinguished from normal pancreas by the overexpression of miR-103 and miR-109, and the lack of miR-155. 46 However, conflicting expression data were reported from studies using both array 45 and PCR-based approaches 45, 47 in that miR-155 was over-expressed in pancreatic ductal adenocarcinomas and cell lines derived from these tumors, which is consistent with solid tumors of other origins. The conflicting reports demonstrate the need to verify altered expression of individual microRNAs using several methodologies.
MicroRNAs Contribute to Cellular Processes Associated With GI Diseases
Important studies have demonstrated that microRNAs regulate tumor suppressors 44, 50 and oncogenes [51] [52] [53] in a variety of tissues (Table 1) . For instance, the let-7 family has been shown to regulate the Ras oncogene and the decreased let-7 expression observed in lung tumors is permissive for Ras over-expression. 53 Therefore, decreased expression of this microRNA results in the over-expression of an oncogene, making let-7 a putative tumor suppressor. Specific examples of microRNA dys-regulation with functional implications for GI cancers include the frequent up-regulation of miR-21. Functional analysis has demonstrated that miR-21 contributes to regulation of the tumor suppressor PTEN in both cholangiocarcinoma and HCC 54 and posttranscriptionally inhibits expression of the tumor suppressor PDCD4 in colorectal cell lines. 50 Several studies also consistently reported miR-21 over-expression in pancreatic adenocarcinomas. Although the functional implications of miR-21 over-expression in this tissue has not been determined, it seems likely, based on studies from other tissues, that this microRNA regulates the expression of relevant tumor suppressor proteins. Furthermore, strong expression of this microRNA predicts limited survival in patients with node-negative pancreatic cancers. 55 
Apoptosis
Apoptosis is an important factor in the pathophysiology of several GI diseases. For instance, in primary liver cancers such as HCC and cholangiocarcinoma, malignant cells resist apoptotic signals, inappropriately surviving oncogenic transformation and often displaying resistance to chemotherapeutic agents. We reported that decreased miR-29b in the cultured malignant cholangiocarcinoma cell line (KMCH) increases Mcl-1 protein expression, compared with nonmalignant human cholangiocytes (H69), and contributes to survival of malignant cells. 52 Datta et al 56 recently reported the methylation-mediated silencing of miR-1-1 in both HCC cell lines and primary HCCs. Reintroduction of this microRNA to HCC cell lines promoted both cell-cycle arrest and apoptosis, possibly through the attenuated expression of the transcription factor FoxP1 and the receptor tyrosine kinase Met. miR-155 is over-expressed in pancreatic tumor samples; this microRNA targets and limits the expression of the stress-induced gene TP53INP1, 57 which promotes p53-dependent apoptosis and is decreased in many pancreatic tumors. Animal models support the importance of microRNAs in apoptosis regulation. For example, Bim expression is increased in mice deficient in miR-17-92 and the mice die of pulmonary hypoplasia, possibly resulting from excessive cell death. 58 
Proliferation and Cell-Cycle Regulation
Increased proliferation accompanies dysregulated apoptosis in many cancers. MicroRNAs regulate the cell cycle and proliferation in many cell types. Gramantieri et al 59 demonstrated that several microRNAs were differentially expressed between HCC and nonneoplastic liver tissues; miR-122 was down-regulated in HCC cells and its expression was inversely correlated with cyclin G1 expression. Furthermore, Shah et al 60 demonstrated that agonistactivated peroxisome proliferator activated receptor-, a member of the steroid hormone nuclear receptor superfamily, altered microRNA expression in a model of hepatocellular proliferation and tumorigenesis. One down-regulated microRNA, let-7c, targets the oncogenic transcription factor c-myc; let-7c down-regulation and the resulting increase in cmyc increased miR-17-92 expression and the proliferative capacity of hepatocytes. Cholangiocyte hyperproliferation was associated with cystogenesis in polycystic liver diseases, most notably with autosomal recessive polycystic kidney disease. Levels of miR-15a were significantly decreased in a cholangiocyte cell line derived from a rat model of autosomal recessive polycystic kidney disease compared with a normal cholangiocyte cell line; this microRNA targets the cell-cycle regulation gene Cdc25A. Transient overexpression of miR-15a ultimately led to decreased protein levels of Cdc25A and numbers of cells in the DNA synthesis phase of the cell cycle. 61 MicroRNAs also contribute to intestinal epithelial cell hyperproliferation-transfection of the commonly dysregulated microRNAs miR-143 or miR-145 into colon cancer cell lines significantly inhibited cell proliferation. Furthermore, manipulation of cellular miR-143 levels altered the expression of ERK5, a mitogen-activated protein kinase that promotes proliferation. 62 
Differentiation
Using a cell culture model of intestinal cell differentiation, Hino et al 63 found that miR-194 was induced and regulated by the transcription factor HNF1 during differentiation. Additionally, overlapping microRNA expression patterns exist between the embryonic colonic mucosa and colorectal cancer. 64 The miR-17-92 cluster increased in embryonic colon mucosa and colorectal cancer tissues; this increase was associated with decreased levels of the transcription factor E2F1, which promotes apoptosis and regulates cell-cycle progression through the tumor suppressor protein Rb. Increased expression of the miR-17-92 cluster of microRNAs has been associated with colonic development, decreased apoptosis, increased proliferation, and cell-cycle progression in various tissues. The functional role of this cluster of microRNAs has been observed in transgenic mice that overexpress the miR-17-92 cluster and develop a lymphoproliferative phenotype. 36 Thus, it is intriguing to speculate that microRNAs have a similar role in human embryogenesis and neoplastic transformation.
Immune Regulation and Pathogen Recognition
MicroRNAs are implicated in the regulation of immune cell differentiation 22, 65 as well as innate 66, 67 and adaptive 32, 33 immune responses. Little is known about the mechanisms that control expression of proteins that contribute to chronic inflammatory diseases of the GI tract (ie, ulcerative colitis, Crohn's disease, primary sclerosing cholangitis, or primary biliary cirrhosis). Although the contribution of microRNAs to chronic inflammatory conditions of the GI tract is unclear, their general contribution to the initiation and attenuation of inflammatory cascades is better understood. In an effort to find candidate microRNAs involved in host cell responses to microbial challenge, Taganov et al 67 analyzed the microRNA expression profile of a monocytic leukemia cell line following TLR stimulation with ligands. Several microRNAs (miR-146a, miR-132, and miR-155) were upregulated after stimulation with the bacterial endotoxin lipopolysaccharide. Functional analysis demonstrated that miR-146a expression is nuclear factor kappa B (NF-B)-dependent and this microRNA targets interleukin-1 receptor-associated kinase and TRAF6, which each activate the TLR and pro-inflammatory cytokine signaling cascades. Therefore, expression of miR-146a has a negative effect on pro-inflammatory signaling in a leukemia cell line. Conversely, in a model of biliary cryptosporidiosis, infection of cultured human cholangiocytes with C parvum (a parasite that causes intestinal and biliary disease) decreased let-7i expression in a MyD88 and NF-B-dependent manner. Decreased let-7i expression resulted in up-regulation of TLR4 in infected cells and increased NF-B signaling. 66 These data raise the possibility that microRNA-regulated posttranscriptional pathways contribute to host-cell responses to microbial infection by increasing inflammatory signaling in response to pathogens 66 or attenuating the inflammatory response. 67 
Clinical Relevance
MicroRNAs for Diagnosis, Prognosis, and Therapy Improved the understanding, detection, and delivery of microRNAs could have clinical value in approaches to GI diseases. Analysis of the microRNA profiles from diseased tissues might aide in diagnosis, allowing pathologists to distinguish between similar conditions, define the origin of a tumor of unknown primary, or distinguish benign from malignant lesions. 38 Alternatively, microRNAs might provide evidence for underlying pathologies 68 and improve de novo diagnosis; assays of sentinal microRNAs in blood, bile, or stool samples could be used to follow progression of a known condition. Additionally, prognostic information could be gained from knowing the expression level of individual microRNAs. Bloomston et al 69 found that high expression levels of miR-196a-2 predicted poor survival of lymph node-positive pancreatic cancer patients and specific microRNA profiles have been associated with increased metastatic potential. 12, 70 This prognostic information may therefore act as a tool for disease management decisions. Further study is required to determine whether there are individual microRNAs or microRNA expression patterns associated with GI diseases that can be used in prognosis, such as determining progression of hepatitis or inflammatory bowel disease. This line of diagnostic and prognostic information will certainly mature as the phenotypic effects of individual microRNA alterations are better understood in the GI tract.
Therapeutically, it seems reasonable to predict that the microRNA profile of a tumor biopsy could be used to direct individualized therapy, based either on empiric correlations between microRNA expression profiles or on mechanism-based alterations in specific pathways caused by microRNA dysregulation. The identification of aberrantly expressed microRNAs and advances in our understanding of the pathways affected by microRNA dysregulation indicate the exciting possibility of therapeutic interventions involving the reintroduction of mature microRNAs (in instances where a microRNA is reduced or absent) or selective inhibition of over-expressed microRNAs (using AMOs). One advantage of microRNAbased therapy, compared with siRNA-based therapy, is that reintroduction of a microRNA results in expression of an endogenous regulator of physiologic processes. However, introducing antisense oligonucleotides to reduce the expression of a microRNA has the potential to generate undesirable off-target effects, although direct modulation of microRNA levels is not the only approach that could be used in microRNA-based therapy. Indeed, some cancers are marked by deficiencies in microRNA processing. 9, 71 In these instances, small molecule activators or repressors of endogenous microRNA processing or expression could affect a cellular phenotype to therapeutic gain.
MicroRNA-based therapies face many of the same considerable challenges as gene therapies, including selectivity, delivery, and efficacy. However, the approaches developed for in vivo delivery of siRNAs or shRNAs, including viral vectors, liposomes, and nanoparticles [72] [73] [74] and specific nucleotide delivery through cell-surface receptor targeting, [75] [76] [77] improve progress toward microRNA-based therapies. There are several examples of successful therapeutic application of RNA interference that use these technologies, typically in tissues that are easily accessible to delivery, such as the retina or lung epithelia. 78, 79 Although obstacles and concerns remain, successful application of microRNA therapies has been established in non-human primates, where antagonism of miR-122, through intraperitoneal delivery of an AMO, significantly lowered plasma cholesterol levels. 80 Although other, more effective cholesterol-lowering therapeutics exist, this accomplishment highlights the opportunity to modulate organ function by controlling microRNA levels. Recently, Santaris Pharma (Denmark) initiated a clinical trial for treatment of HCV infection using SPC3649, an AMO that targets miR-122. Although SPC3649 is the only microRNA antagomir currently in clinical trials, other groups are likely to evaluate the therapeutic efficacy of other microRNA-based therapies. microRNAs have an important role in normal and pathologic cellular processes in the GI tract; their roles in effecting coordinated changes in expression of multiple proteins places these regulators in prime position for their utility in diagnosis, prognosis, and treatment of complex conditions. Biogenesis and processing of microRNAs. MicroRNAs are endogenous, non-protein-coding genes that are transcribed and ultimately processed into 20-22 nucleotide single-stranded RNA molecules. As indicated above and in the text, the production of a mature microRNA and ultimately translation inhibition is a highly regulated process. 
